ReviewRadiographics : a review publication of the Radiological Society of North America, Inc
Radiofrequency ablation of lung tumors: imaging features of the postablation zone.
Review in Radiographics : a review publication of the Radiological Society of North America, Inc. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Expert consensus on image-guided radiofrequency ablation of pulmonary tumors: 2018 edition.Thoracic cancer · 2018Guideline
- CT Densitometry and Morphology of Radiofrequency-Ablated Stage IA Non-Small Cell Lung Cancer: Results from the American College of Surgeons Oncology Group Z4033 (Alliance) Trial.Journal of vascular and interventional radiology : JVIR · 2020Trial
- Radiofrequency ablation of stage IA non-small cell lung cancer in patients ineligible for surgery: results of a prospective multicenter phase II trial.Journal of cardiothoracic surgery · 2018Trial
- Article
- Quantitative assessment of thermal ablation in small animal tumor models: implications for pre-clinical studies of combination treatments.Physics in medicine and biology · 2025Article
- Fiber Bragg Grating Thermometry and Post-Treatment Ablation Size Analysis of Radiofrequency Thermal Ablation on Ex Vivo Liver, Kidney and Lung.Sensors (Basel, Switzerland) · 2025Article
- Article
- Discrepancy Between Achieved and Vendor-Predicted Ablation Zones in the Lung: Contributing Factors.Cardiovascular and interventional radiology · 2024Article
- Cone-beam computed tomography image-guided percutaneous microwave ablation for lung nodules in a hybrid operating room: an initial experience.European radiology · 2024Article
- Habitat-based radiomics analysis for evaluating immediate response in colorectal cancer lung metastases treated by radiofrequency ablation.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Safety and local efficacy of computed tomography-guided microwave ablation for treating early-stage non-small cell lung cancer adjacent to bronchovascular bundles.European radiology · 2024Article
- Imaging Follow-Up of Nonsurgical Therapies for Lung Cancer:AJR. American journal of roentgenology · 2023Review
- International expert consensus on diagnosis and treatment of lung cancer complicated by chronic obstructive pulmonary disease.Translational lung cancer research · 2023Review
- Radiofrequency ablation of lung metastases of colorectal cancer: could early radiomics analysis of the ablation zone help detect local tumor progression?The British journal of radiology · 2023Article
- A CT-based radiomics approach to predict immediate response of radiofrequency ablation in colorectal cancer lung metastases.Frontiers in oncology · 2023Article
- Comparison of expected imaging findings following percutaneous microwave and cryoablation of pulmonary tumors: ablation zones and thoracic lymph nodes.European radiology · 2022Article
- Cytoreductive Surgical Treatment of Pleural Mesothelioma in a Porcine Model Using Magnetic-Resonance-Guided Focused Ultrasound Surgery (MRgFUS) and Radiofrequency Ablation (RFA).Tomography (Ann Arbor, Mich.) · 2022Article
- A comparative analysis of thermal ablation techniques in the treatment of primary and secondary lung tumors: a single-center experience.La Radiologia medica · 2022Article
- CT after Lung Microwave Ablation: Normal Findings and Evolution Patterns of Treated Lesions.Tomography (Ann Arbor, Mich.) · 2022Article
- Augmented fluoroscopy guided transbronchial pulmonary microwave ablation using a steerable sheath.Translational lung cancer research · 2022Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
Radiofrequency ablation (RFA) is used to treat pulmonary malignancies. Although preliminary results are suggestive of a survival benefit, local progression rates are appreciable. Because a patient can undergo repeat treatment if recurrence is detected early, reliable post-RFA imaging follow-up is critical. The purpose of this article is to describe (a) an algorithm for post-RFA imaging surveillance; (b) the computed tomographic (CT) appearance, size, enhancement, and positron emission tomographic (PET) metabolic activity of the ablation zone; and (c) CT, PET, and dual-modality imaging with PET and CT (PET/CT) features suggestive of partial ablation or tumor recurrence and progression. CT is routinely used for post-RFA follow-up. PET and PET/CT have emerged as auxiliary follow-up techniques. CT with nodule densitometry may be used to supplement standard CT. Post-RFA follow-up was divided into three phases: early (immediately after to 1 week after RFA), intermediate (>1 week to 2 months), and late (>2 months). CT and PET imaging features suggestive of residual or recurrent disease include (a) increasing contrast material uptake in the ablation zone (>180 seconds on dynamic images), nodular enhancement measuring more than 10 mm, any central enhancement greater than 15 HU, and enhancement greater than baseline anytime after ablation; (b) growth of the RFA zone after 3 months (compared with baseline) and definitely after 6 months, peripheral nodular growth and change from ground-glass opacity to solid opacity, regional or distant lymph node enlargement, and new intrathoracic or extrathoracic disease; and (c) increased metabolic activity beyond 2 months, residual activity centrally or at the ablated tumor, and development of nodular activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.